Phase I/II trial evaluating toxicity and efficacy of adding stereotactic body radiotherapy to sorafenib in patients with metastatic, recurrent, or unresectable renal cell cancer.
Phase of Trial: Phase I/II
Latest Information Update: 16 Nov 2009
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SBRT-RCC
- 17 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Jul 2009 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 27 May 2008 New trial record.